Hong Xu

This inventor holds 16 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Bispecific Antibodies. Top assignees: Memorial Sloan Kettering Cancer Center, Massachusetts Institute of Technology. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Xu. Retrieved from https://idiyas.com/inventor/hong-xu-wd4f8dq6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 6)

% Patents Active = 87.5

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 36(Granted Patents)

Company Filing History:

16 out of 621

Memorial Sloan Kettering Cancer Center

patents

2 out of 8,600

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Immunotherapy

Anti-Tumor Antigens

Multi-Specific Antibodies

Radioimmunotherapy

HER2 Binding Molecules

IL-15 Complexes

A33 Antigen

DOTA Compositions

Anti-L1-CAM

Anti-GD2 Antibodies

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729246 - ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF (2026-09-08),

2. 12714758 - DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy (2026-08-25),

3. 12630632 - BISPECIFIC HER2 AND CD3 BINDING MOLECULES (2026-05-19),

4. 12497435 - MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY (2025-12-16),

5. 12486323 - ANTI-L1-CAM ANTIBODIES AND USES THEREOF (2025-12-02),

6. 11987642 - Bispecific HER2 and CD3 binding molecules (2024-05-21),

7. 11858993 - Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof (2024-01-02),

8. 11820832 - Bispecific HER2 and CD3 binding molecules (2023-11-21),

9. 11597764 - Anti-L1-CAM antibodies and uses thereof (2023-03-07),

10. 11555072 - A33 antibody compositions and methods of using the same in radioimmunotherapy (2023-01-17),

11. 11046768 - Bispecific HER2 and CD3 binding molecules (2021-06-29),

12. 10988534 - Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof (2021-04-27),

13. 10519248 - Bispecific HER2 and CD3 binding molecules (2019-12-31),

14. 10287365 - Anti-GD2 antibodies (2019-05-14),

15. 9688772 - Anti-GD2 antibodies (2017-06-27),

Title: Innovations and Contributions of Inventor Hong Xu

Introduction

Hong Xu is a prominent inventor based in New York, NY, with a remarkable portfolio of 11 patents. His work primarily focuses on the development of innovative therapeutic solutions for managing and treating various disorders, particularly in the field of oncology.

Latest Patents

Among his latest patents, Xu has developed bispecific HER2 and CD3 binding molecules. These compositions and methods are designed to specifically bind to HER2, a receptor tyrosine kinase, and CD3, a T cell receptor. This innovative approach mediates T cell cytotoxicity, offering potential management and treatment options for disorders such as cancer. Additionally, he has created multi-specific antibodies with affinity for the human A33 antigen and DOTA metal complex. These multi-specific binding agents are intended for the detection, prevention, and therapeutic treatment of diseases characterized by the expression of the A33 glycoprotein antigen, particularly colorectal cancer.

Career Highlights

Hong Xu has made significant contributions to the field of medical research through his work at prestigious institutions. He has been associated with the Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, where he has furthered his research and innovation in cancer treatment.

Collaborations

Some of his notable coworkers include Nai-Kong V Cheung and Andres Lopez-Albaitero, who have collaborated with him on various projects aimed at advancing cancer therapies.

Conclusion

Hong Xu's innovative contributions and extensive patent portfolio highlight his dedication to improving cancer treatment methodologies. His work continues to inspire advancements in the medical field, showcasing the importance of innovation in addressing complex health challenges.

Profile summary based on public USPTO records.